Literature DB >> 8822476

The effect of the acute and chronic administration of CP 96,345, a selective neurokinin1 receptor antagonist, on midbrain dopamine neurons in the rat: a single unit, extracellular recording study.

Y Minabe1, K Emori, A Toor, G E Stutzmann, C R Ashby.   

Abstract

In this study, we examined the effect of acute and chronic administration of the selective neurokinin1 receptor antagonist CP 96,345 on the basal activity of spontaneously active dopamine (DA) neurons in the substantia nigra pars compacta (SNC) and the ventral tegmental area (VTA). This was accomplished using the technique of in vivo, extracellular single unit recording in anesthetized rats. The intravenous (i.v.) administration of CP 96,345 (0.01-1.28 mg/kg) did not significantly alter the firing rate of spontaneously active DA neurons in the SNC and VTA areas. The acute administration of 5 or 10 mg/kg, i.p., of CP 96,345 produced a significant decrease in the number of spontaneously active SNC and VTA dopamine cells compared to vehicle-treated rats. In contrast to its effect on the number of spontaneously active DA neurons, the administration of 5 mg/kg, i.p., of CP 96,345 did not significantly alter the basal firing pattern of either SNC or VTA DA neurons. The acute administration of CP 96,345 (10 mg/kg, i.p.) significantly potentiated the suppressant action of (+)-apomorphine on the basal firing rate of spontaneously active SNC and VTA DA cells. The chronic administration of CP 96,345 (5 or 10 mg/kg, i.p.) for 21 days also produced a significant decrease in the number of spontaneously active SNC and VTA DA cells compared to vehicle controls. This effect was not reversed by the systemic administration of (+)-apomorphine (50 micrograms/kg, i.v.), suggesting that the reduction in the number of spontaneously active DA cells produced by CP 96,345 is probably not the result of depolarization inactivation. Overall, our results indicate that the tonic activation of NK1 receptors by substance P may be necessary to maintain the spontaneous activity of a proportion of midbrain DA neurons.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822476     DOI: 10.1002/(SICI)1098-2396(199601)22:1<35::AID-SYN4>3.0.CO;2-J

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  4 in total

1.  Neurokinin-1 receptor activation in globus pallidus.

Authors:  Lei Chen; Qiao-Ling Cui; Wing-Ho Yung
Journal:  Front Neurosci       Date:  2009-10-26       Impact factor: 4.677

2.  Neurokinin-1 receptors in cholinergic neurons of the rat ventral pallidum have a predominantly dendritic distribution that is affected by apomorphine when combined with startle-evoking auditory stimulation.

Authors:  E Mengual; J Chan; D Lane; M San Luciano Palenzuela; Y Hara; A Lessard; V M Pickel
Journal:  Neuroscience       Date:  2007-12-04       Impact factor: 3.590

Review 3.  The pharmacology of neurokinin receptors in addiction: prospects for therapy.

Authors:  Alexander J Sandweiss; Todd W Vanderah
Journal:  Subst Abuse Rehabil       Date:  2015-09-07

Review 4.  Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders.

Authors:  Chelsea A Vadnie; Jun Hyun Park; Noha Abdel Gawad; Ada Man Choi Ho; David J Hinton; Doo-Sup Choi
Journal:  Front Neurosci       Date:  2014-09-18       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.